Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of “Reduce” from Brokerages

Minerva Neurosciences, Inc (NASDAQ:NERV) has been given an average rating of “Reduce” by the four brokerages that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.50.

A number of research firms have recently commented on NERV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Wednesday, June 24th. Zacks Research cut shares of Minerva Neurosciences from a “hold” rating to a “strong sell” rating in a report on Wednesday. Jefferies Financial Group raised shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating in a research note on Friday. Finally, Wall Street Zen upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 8th.

Institutional Trading of Minerva Neurosciences

Several institutional investors and hedge funds have recently modified their holdings of NERV. Federated Hermes Inc. boosted its holdings in shares of Minerva Neurosciences by 297.5% in the fourth quarter. Federated Hermes Inc. now owns 5,371,775 shares of the biopharmaceutical company’s stock valued at $21,595,000 after purchasing an additional 4,020,500 shares during the period. Renaissance Technologies LLC increased its holdings in Minerva Neurosciences by 28.1% during the 4th quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 32,700 shares during the period. State Street Corp increased its holdings in Minerva Neurosciences by 45.4% during the 4th quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 7,500 shares during the period. Vivo Capital LLC bought a new stake in Minerva Neurosciences during the 4th quarter valued at $17,377,000. Finally, Spruce Street Capital LP bought a new stake in Minerva Neurosciences during the 4th quarter valued at $6,655,000. Institutional investors own 34.56% of the company’s stock.

More Minerva Neurosciences News

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright’s longer-term projections remain optimistic, calling for positive EPS of $0.64 in fiscal 2029 and $1.67 in fiscal 2030. This indicates the firm still sees potential for meaningful profitability if Minerva’s development programs and commercialization plans succeed.
• Neutral Sentiment: The analyst forecasts EPS of negative $0.15 for fiscal 2028, followed by a return to profitability in 2029. The estimates imply that investors may need to look several years ahead for earnings growth.
• Negative Sentiment: HC Wainwright cut its fiscal 2026 EPS estimate to negative $0.50 from negative $0.20 and reduced its Q3 2026 estimate to negative $0.14 from negative $0.01. The firm also expects Q4 2026 EPS of negative $0.09, compared with its previous estimate of negative $0.01.
• Negative Sentiment: Forecasts for fiscal 2027 were sharply lowered to negative $0.42 per share from positive $4.82. Quarterly 2027 estimates were also reset to approximately negative $0.11 per share, including Q2, Q3 and Q4, signaling substantially weaker near-term earnings expectations.

Minerva Neurosciences Stock Performance

Shares of NERV opened at $3.92 on Friday. Minerva Neurosciences has a twelve month low of $1.79 and a twelve month high of $12.46. The company has a market cap of $187.18 million, a P/E ratio of -0.14 and a beta of -0.10. The company’s fifty day simple moving average is $4.46 and its 200-day simple moving average is $5.43.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. Analysts predict that Minerva Neurosciences will post -0.5 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.